• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估英国威尔士地区感染奥密克戎或德尔塔变异株后再次感染 SARS-CoV-2 的风险。

Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK.

机构信息

Communicable Disease Surveillance Centre (CDSC), Public Health Wales, Cardiff, Wales, United Kingdom.

Pathogen Genomics Unit, Public Health Wales, Cardiff, Wales, United Kingdom.

出版信息

PLoS One. 2024 Sep 6;19(9):e0309645. doi: 10.1371/journal.pone.0309645. eCollection 2024.

DOI:10.1371/journal.pone.0309645
PMID:39240934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11379141/
Abstract

Recent studies suggest an increased risk of reinfection with the SARS-CoV-2 Omicron variant compared with previous variants, potentially due to an increased ability to escape immunity specific to older variants, high antigenic divergence of Omicron from earlier virus variants as well as its altered cell entry pathway. The present study sought to investigate epidemiological evidence for differential SARS-CoV-2 reinfection intervals and incidence rates for the Delta versus Omicron variants within Wales. Reinfections in Wales up to February 2022 were defined using genotyping and whole genome sequencing. The median inter-infection intervals for Delta and Omicron were 226 and 192 days, respectively. An incidence rate ratio of 2.17 for reinfection with Omicron compared to Delta was estimated using a conditional Poisson model, which accounted for several factors including sample collection date, age group, area of residence, vaccination and travel status. These findings are consistent with an increased risk of reinfection with the Omicron variant, and highlight the value of monitoring emerging variants that have the potential for causing further waves of cases.

摘要

最近的研究表明,与以前的变异株相比,感染 SARS-CoV-2 的奥密克戎变异株的再感染风险增加,这可能是由于其能够更有效地逃避针对旧变异株的特异性免疫、奥密克戎与早期病毒变异株的抗原差异较大以及其改变的细胞进入途径。本研究旨在调查威尔士境内德尔塔变异株与奥密克戎变异株再感染间隔时间和发病率的流行病学证据。截至 2022 年 2 月,通过基因分型和全基因组测序来确定威尔士的再感染病例。德尔塔和奥密克戎的中位再感染间隔分别为 226 天和 192 天。使用条件泊松模型估计奥密克戎与德尔塔相比的再感染发生率比为 2.17,该模型考虑了多个因素,包括样本采集日期、年龄组、居住地区、疫苗接种和旅行状态。这些发现与奥密克戎变异株再感染风险增加一致,并强调了监测可能导致进一步病例浪潮的新型变异株的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/891518aa669c/pone.0309645.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/1fd06b33e675/pone.0309645.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/1f490466070a/pone.0309645.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/1fa5e4d0760b/pone.0309645.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/891518aa669c/pone.0309645.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/1fd06b33e675/pone.0309645.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/1f490466070a/pone.0309645.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/1fa5e4d0760b/pone.0309645.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f0d/11379141/891518aa669c/pone.0309645.g004.jpg

相似文献

1
Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK.评估英国威尔士地区感染奥密克戎或德尔塔变异株后再次感染 SARS-CoV-2 的风险。
PLoS One. 2024 Sep 6;19(9):e0309645. doi: 10.1371/journal.pone.0309645. eCollection 2024.
2
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.疫苗对 Alpha、Delta 或奥密克戎变异株流行期间 SARS-CoV-2 再感染的有效性:一项丹麦全国性研究。
PLoS Med. 2022 Nov 22;19(11):e1004037. doi: 10.1371/journal.pmed.1004037. eCollection 2022 Nov.
3
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.新加坡一项全国性队列研究:SARS-CoV-2 感染和疫苗对有医疗记录的奥密克戎 BA.4、BA.5 和 XBB 再感染相关症状的保护免疫作用。
Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.
4
Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022.2020 年 2 月至 2022 年 1 月期间,挪威全国性研究:SARS-CoV-2 再感染的频率和风险。
BMC Public Health. 2024 Jan 15;24(1):181. doi: 10.1186/s12889-024-17695-8.
5
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study.与 SARS-CoV-2 变体 B.1.1.7 相关的症状学变化、再感染和传染性:一项生态学研究。
Lancet Public Health. 2021 May;6(5):e335-e345. doi: 10.1016/S2468-2667(21)00055-4. Epub 2021 Apr 12.
6
SARS-CoV-2 reinfection with Omicron variant in Shaanxi Province, China: December 2022 to February 2023.中国陕西省 2022 年 12 月至 2023 年 2 月期间发生的奥密克戎变异株再感染 SARS-CoV-2。
BMC Public Health. 2024 Feb 16;24(1):496. doi: 10.1186/s12889-024-17902-6.
7
SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.奥密克戎变异株的 SARS-CoV-2 再感染率高于阿尔法和德尔塔变异株。
Ir J Med Sci. 2023 Apr;192(2):751-756. doi: 10.1007/s11845-022-03060-4. Epub 2022 Jun 17.
8
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.英国普通人群在多次奥密克戎变异株波期间感染 SARS-CoV-2 的风险。
Nat Commun. 2024 Feb 2;15(1):1008. doi: 10.1038/s41467-024-44973-1.
9
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月,英国青少年在先前感染和接种疫苗后对 delta(B.1.617.2)和 omicron(B.1.1.529)BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用:一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
10
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.奥密克戎变异株与新冠前变异株相比,既往感染 SARS-CoV-2 在预防再感染和 COVID-19 严重并发症方面的作用:系统评价。
BMC Infect Dis. 2023 Jun 26;23(1):432. doi: 10.1186/s12879-023-08328-3.

引用本文的文献

1
Coronavirus-two infection among adults: A scoping review of literature published in 2023-24.2023 - 2024年发表文献的范围综述:成人中的新型冠状病毒2感染
Pak J Med Sci. 2025 Jun;41(6):1788-1798. doi: 10.12669/pjms.41.6.12201.

本文引用的文献

1
Insights from an N3C RECOVER EHR-based cohort study characterizing SARS-CoV-2 reinfections and Long COVID.一项基于N3C RECOVER电子健康记录的队列研究对SARS-CoV-2再感染和长期新冠的见解。
Commun Med (Lond). 2024 Jul 11;4(1):129. doi: 10.1038/s43856-024-00539-2.
2
Changing risk factors for developing SARS-CoV-2 infection from Delta to Omicron.Delta 株向 Omicron 株变异时发生 SARS-CoV-2 感染的风险因素变化。
PLoS One. 2024 May 15;19(5):e0299714. doi: 10.1371/journal.pone.0299714. eCollection 2024.
3
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.
英国普通人群在多次奥密克戎变异株波期间感染 SARS-CoV-2 的风险。
Nat Commun. 2024 Feb 2;15(1):1008. doi: 10.1038/s41467-024-44973-1.
4
Risk of SARS-CoV-2 Reinfection 3 Years after the Start of the Pandemic: A Population-Level Observational Study.大流行开始3年后再次感染SARS-CoV-2的风险:一项基于人群水平的观察性研究。
Life (Basel). 2023 Oct 24;13(11):2111. doi: 10.3390/life13112111.
5
Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.威尔士 COVID-19 疫苗接种普及率的平等维度:多变量关联数据人群分析。
Vaccine. 2023 Nov 30;41(49):7333-7341. doi: 10.1016/j.vaccine.2023.10.066. Epub 2023 Nov 4.
6
Reinfection rates, change in antibody titers and adverse events after COVID-19 vaccination among patients previously infected with COVID-19 in Metro Manila, Philippines: a secondary analysis of a completed cohort study.在菲律宾马尼拉大都会区,先前感染过 COVID-19 的患者在接种 COVID-19 疫苗后的再感染率、抗体滴度变化和不良事件:一项已完成队列研究的二次分析。
BMC Infect Dis. 2023 Nov 1;23(1):750. doi: 10.1186/s12879-023-08743-6.
7
Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged ≥18 Years - 18 U.S. Jurisdictions, September 2021-December 2022.2021 年 9 月至 2022 年 12 月 18 个美国司法管辖区≥18 岁成年人中经实验室确认的 SARS-CoV-2 再感染趋势以及相关住院和死亡情况。
MMWR Morb Mortal Wkly Rep. 2023 Jun 23;72(25):683-689. doi: 10.15585/mmwr.mm7225a3.
8
Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.奥密克戎(B.1.1.529)变体及其亚变体和谱系会在全球引发新一轮新冠疫情吗?——当前证据及应对策略概述
Int J Surg Open. 2023 Jun;55:100625. doi: 10.1016/j.ijso.2023.100625. Epub 2023 May 18.
9
Serosurveillance of SARS-CoV-2 in Welsh Blood Donors: Establishment of the surveillance system and results up to November 2022.威尔士献血者中 SARS-CoV-2 的血清学监测:监测系统的建立及截至 2022 年 11 月的结果。
Euro Surveill. 2023 May;28(19). doi: 10.2807/1560-7917.ES.2023.28.19.2200473.
10
Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.全球 2019 冠状病毒病再感染的流行率:系统评价和荟萃分析。
BMC Public Health. 2023 Apr 28;23(1):778. doi: 10.1186/s12889-023-15626-7.